The Usage of Cryopreserved Reproductive Material in Cancer Patients Undergoing Fertility Preservation Procedures
Author:
Wnuk Katarzyna12ORCID, Świtalski Jakub3ORCID, Miazga Wojciech12ORCID, Tatara Tomasz14ORCID, Religioni Urszula2ORCID, Olszewski Paweł5, Augustynowicz Anna3
Affiliation:
1. Department of Health Policy Programs, Department of Health Technology Assessment, Agency for Health Technology Assessment and Tariff System, 00032 Warsaw, Poland 2. School of Public Health, Centre of Postgraduate Medical Education of Warsaw, Kleczewska 61/63, 01826 Warsaw, Poland 3. Department of Health Economics and Medical Law, Faculty of Health Sciences, Medical University of Warsaw, 01445 Warsaw, Poland 4. Department of Public Health, Faculty of Health Sciences, Medical University of Warsaw, 02091 Warsaw, Poland 5. Medical Faculty, Lazarski University, 02662 Warsaw, Poland
Abstract
Background: Many cancer treatment methods can affect fertility by damaging the reproductive organs and glands that control fertility. Changes can be temporary or permanent. In order to preserve the fertility of cancer patients and protect the genital organs against gonadotoxicity, methods of fertility preservation are increasingly used. Considering that some patients ultimately decide not to use cryopreserved reproductive material, this review analysed the percentage of post-cancer patients using cryopreserved reproductive material, collected before treatment as part of fertility preservation. Methods: A systematic search of studies was carried out in accordance with the Cochrane Collaboration guidelines, based on a previously prepared research protocol. The search was conducted in Medline (via PubMed), Embase (via OVID), and the Cochrane Library. In addition, a manual search was performed for recommendations/clinical practice guidelines regarding fertility preservation in cancer patients. Results: Twenty-six studies met the inclusion criteria. The studies included in the review discussed the results of cryopreservation of oocytes, embryos, ovarian tissue, and semen. In 10 studies, the usage rate of cryopreserved semen ranged from 2.6% to 21.5%. In the case of cryopreserved female reproductive material, the return/usage rate ranged from 3.1% to 8.7% for oocytes, approx. 9% to 22.4% for embryos, and 6.9% to 30.3% for ovarian tissue. In studies analysing patients’ decisions about unused reproductive material, continuation of material storage was most often indicated. Recovering fertility or death of the patient were the main reasons for rejecting cryopreserved semen in the case of men. Conclusion: Fertility preservation before gonadotoxic treatment is widely recommended and increasingly used in cancer patients. The usage rate is an important indicator for monitoring the efficacy of these methods. In all of the methods described in the literature, this indicator did not exceed 31%. It is necessary to create legal and organizational solutions regulating material collection and storage and to create clear paths for its usage in the future, including by other recipients.
Funder
Medical University of Warsaw
Subject
Cancer Research,Oncology
Reference72 articles.
1. World Health Organization (2023, June 13). ICD-11 for Mortality and Morbidity Statistics (Version: 01/2023). Female Infertility, Available online: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/1237004558. 2. International Agency for Research on Cancer (World Health Organization) (2023, June 13). ICD-11 for Mortality and Morbidity Statistics (Version: 01/2023). Male Infertility, Available online: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/753457327. 3. (2023, June 13). Estimated Number of New Cases in 2020, World, Both Sexes, Ages 15–49. Available online: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=3&ages_group%5B%5D=9&group_cancer=1&include_nmsc=1&include_nmsc_other=1. 4. Hao, X., Anastácio, A., Liu, K., and Rodriguez-Wallberg, K.A. (2019). Ovarian Follicle Depletion Induced by Chemotherapy and the Investigational Stages of Potential Fertility-Protective Treatments—A Review. Int. J. Mol. Sci., 20. 5. Demeestere, I., Moffa, F., Peccatori, F., Poirot, C., and Shalom-Paz, E. (2012). Multiple Approaches for Individualized Fertility Protective Therapy in Cancer Patients. Obstet. Gynecol. Int., 2012.
|
|